tiprankstipranks
Calidi Biotherapeutics Faces Warrant Delisting by NYSE
Company Announcements

Calidi Biotherapeutics Faces Warrant Delisting by NYSE

Calidi Biotherapeutics ( (CLDI) ) has shared an announcement.

Pick the best stocks and maximize your portfolio:

Calidi Biotherapeutics, a biotechnology company specializing in targeted antitumor therapies, has been notified by the NYSE that its warrants, trading under CLDI WS, will be delisted due to low trading prices. However, trading of Calidi’s common stock, CLDI, remains unaffected. The company is exploring options to appeal the decision. Calidi continues its focus on developing innovative cancer treatments through its stem cell-based platforms.

Find detailed analytics on CLDI stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyCalidi files to sell 6.94M shares of common stock for holders
TipRanks Auto-Generated NewsdeskCalidi Biotherapeutics Reveals Promising Virotherapy Data
TheFlyCalidi presents data on RTNova systemic technology in metastatic lung cancer
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App